A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study
-
Published:2022-02-25
Issue:4
Volume:407
Page:1345-1356
-
ISSN:1435-2451
-
Container-title:Langenbeck's Archives of Surgery
-
language:en
-
Short-container-title:Langenbecks Arch Surg
Author:
Matsumura Masaru, Hasegawa KiyoshiORCID, Oba Masaru, Yamaguchi Kensei, Uetake Hiroyuki, Yoshino Takayuki, Morita Satoshi, Takahashi Keiichi, Unno Michiaki, Shimada Yasuhiro, Muro Kei, Matsuhashi Nobuhisa, Mori Masaki, Baba Hideo, Shimada Mitsuo, Mise Yoshihiro, Kawaguchi Yoshikuni, Kagimura Tatsuo, Ishigure Kiyoshi, Saiura Akio, Sugihara Kenichi, Kokudo Norihiro
Funder
translational research center for medical innovation in kobe
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1–34. https://doi.org/10.1007/s10147-017-1101-6 2. Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Watanabe T, Makuuchi M, Kokudo N (2016) Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial. PLoS ONE 11:e0162400. https://doi.org/10.1371/journal.pone.0162400 3. Kawaguchi Y., Kopetz S., Newhook T. E., De Bellis M., Chun Y. S., Tzeng C. D., Aloia T. A., and Vauthey J. N. (2019) Mutation Status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases clin cancer Res 25:5843–5851. https://doi.org/10.1158/1078-0432.Ccr-19-0863 4. Kawaguchi Y, Lillemoe HA, Panettieri E, Chun YS, Tzeng CD, Aloia TA, Kopetz S, Vauthey JN (2019) Conditional recurrence-free survival after resection of colorectal liver metastases: persistent deleterious association with RAS and TP53 co-mutation. J Am Coll Surg 229:286-294.e281. https://doi.org/10.1016/j.jamcollsurg.2019.04.027 5. Saiura A, Yamamoto J, Hasegawa K, Koga R, Sakamoto Y, Hata S, Makuuchi M, Kokudo N (2012) Liver resection for multiple colorectal liver metastases with surgery up-front approach: bi-institutional analysis of 736 consecutive cases. World J Surg 36:2171–2178. https://doi.org/10.1007/s00268-012-1616-y
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|